Table 2 Outcomes by gender and treatment group
| Â | Women | Men | ||||||
|---|---|---|---|---|---|---|---|---|
| Â | Olanzapine | Haloperidol | Olanzapine | Haloperidol | ||||
Outcome measure | Baseline | Endpoint | Baseline | Endpoint | Baseline | Endpoint | Baseline | Endpoint |
Core symptoms | Â | Â | Â | Â | Â | Â | Â | Â |
   BPRS positive | 10.1 (4.0) | 6.5 (4.8) | 9.9 (4.3) | 6.9 (4.4) | 10.3 (4.1) | 7.0 (4.6) | 10.7 (4.0) | 8.0 (4.6) |
   BPRS negative* | 6.6 (3.3) | 4.4 (3.1) | 6.8 (3.4) | 5.5 (3.3) | 6.7 (3.2) | 4.8 (2.9) | 6.8 (3.5) | 5.5 (3.2) |
Depressive symptoms | Â | Â | Â | Â | Â | Â | Â | Â |
   MADRS* | 17.8 (9.6) | 11.0 (9.3) | 16.1 (8.6) | 13.5 (10.7) | 16.0 (8.4) | 10.5 (7.7) | 17.0 (8.7) | 13.7 (9.4) |
   BPRS anxiety & depression* | 8.1 (3.8) | 5.0 (4.0) | 7.8 (4.1) | 6.0 (4.3) | 7.1 (3.7) | 4.5 (3.6) | 7.7 (3.9) | 5.7 (3.9) |
Functioning | Â | Â | Â | Â | Â | Â | Â | Â |
   SF-36 mental component* | 34.7 (13.1) | 41.8 (12.1) | 34.2 (12.4) | 36.5 (13.0) | 34.6 (12.4) | 40.6 (12.0) | 34.7 (11.7) | 37.8 (12.3) |
   SF-36 physical component* | 41.3 (14.3) | 45.0 (13.9) | 41.9 (13.5) | 42.1 (13.8) | 44.7 (12.2) | 48.7 (11.6) | 43.9 (13.2) | 45.4 (13.1) |
Weight | Â | Â | Â | Â | Â | Â | Â | Â |
   Weight, kg* †| 68.9 (15.5) | 70.5 (15.8) | 72.6 (17.8) | 72.4 (17.6) | 80.3 (15.9) | 82.5 (16.2) | 80.7 (17.1) | 81.0 (17.4) |
   BMI* †| 26.1 (5.4) | 26.7 (5.5) | 27.2 (6.6) | 27.1 (6.5) | 25.8 (4.8) | 26.5 (4.9) | 25.7 (5.0) | 25.8 (5.0) |